(Q46168968)

English

Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin

scientific article published on 23 June 2005

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

author name string

D J van Rensburg

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

C Fogarty

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

S Kohno

3

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

L Dunbar

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

M Rangaraju

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

R Nusrat

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

publication date

23 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

51

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

186-192

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Comparative antimicrobial susceptibility of respiratory tract pathogens

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

The activity of levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999 and 2000.

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Efficacy and safety of telithromycin in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Ketolides-telithromycin, an example of a new class of antibacterial agents

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Erythromycin resistance by ribosome modification

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Macrolide resistance among invasive Streptococcus pneumoniae isolates

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Failure of Macrolide Antibiotic Treatment in Patients with Bacteremia Due to Erythromycin‐Resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1159%2F000086576

21 January 2018

Identifiers

10.1159/000086576

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/15980629

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46168968&oldid=2096481540"